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Background and PurposeaaCerebral white matter (WM) lesions are frequently observed in 
human cerebrovascular diseases, and are believed to be responsible for cognitive impairment. 
Various neuroprotective agents can suppress this type of WM or neuronal damage. In this study, 
we investigated whether citicoline, a drug used to treat acute ischemic stroke, can attenuate 
WM lesions and cognitive decline caused by chronic hypoperfusion in the rat. 
MethodsaaAnimals were divided into immediate- and delayed-treatment groups. Those in the 
immediate-treatment group received a sham operation, citicoline (500 mg/kg/day), or phosphate 
buffered saline (PBS) treatment. Citicoline or PBS was administered intraperitoneally for 21 days 
after occluding the bilateral common carotid arteries. Rats in the delayed-treatment group were 
intraperitoneally administered with either 500 mg/kg/day citicoline or PBS for 21 days beginn-
ing on the 8th day after the operation. From the 17th day of administration, the rats were placed 
in an eight-arm radial maze to examine their cognitive abilities. After completing the administ-
ration, tissues were isolated for Klüver-Barrera and the terminal deoxynucleotidyl transferase 
biotin-dUTP nick end labelling (TUNEL) staining. 
ResultsaaIn the immediate-treatment group, cognitive functions were preserved in the citicoline-
treated group, and WM damage and TUNEL-positive cells differed significantly between the 
citicoline- and PBS-treated animals. In the delayed-treatment group, there was no decrease in 
WM damage and TUNEL-positive cells, but cognitive improvement was evident for citicoline 
treatment relative to PBS treatment. 
ConclusionsaaThese results show that citicoline can prevent WM damage and aid cognitive 
improvement, even after a certain extent of disease progression. Citicoline might be useful in pa-
tients with acute ischemic stroke as well as in chronic stroke accompanied with cognitive im-
pairment.  J Clin Neurol 2009;5:33-38
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Introduction 
 
Vascular dementia is a subtype of dementia, and its prevalence 
is second to that of Alzheimer’s disease in westernized socie-
ties.
1 Vascular dementia causes many neuropsychiatric and 
physical problems, and represents a significant economic bur-
den. Brain imaging studies have revealed obvious changes in 
the cerebral white matter (WM) rather than in the cortex, and 
hence WM lesions are thought to be the core pathology for 
cognitive declines in patients with vascular dementia.
2,3 It is 
known that WM damage is caused by widespread demyelina-
tion and axonal loss in the WM;
4 however, the mechanisms 
underlying the pathologic changes are not fully understood. 
Cerebral WM lesions are probably caused by chronic ce-
rebral ischemia, and they can indeed be experimentally indu-
ced in the rat brain by permanent occlusion of both common 
carotid arteries,
5 which can affect cognitive function,
6 and 
this model is similar to that of vascular dementia.
7 This tech-
nique can decrease the blood flow in the cerebral cortex and 
hippocampus by up to 40-82%
8-10 for several months, which 
induces certain learning disorders. Thus, this technique can 
be used to study vascular dementia and cerebral WM lesions. 
It has been reported that citicoline (exogenous cytidine-5-
diphosphocholine), a substance synthesized by Eugene Ke- 
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nnedy in 1956, is effective in treating ischemia in the central 
nervous system, brain trauma, and Parkinson’s disease.
11 Ci-
ticoline is a precursor of phosphatidylcholine (PtdCho) bio-
synthesis, and an increase in PtdCho biosynthesis prevents 
apoptosis of neurons and protects against neuronal damage.
12 
In addition, citicoline maintains cardiolipin and sphingomyelin 
levels, stimulates glutathione biosynthesis, activates glutathi-
one reductase, and reduces lipid peroxidation.
12 Therefore, 
citicoline is expected to prevent apoptosis and delay disease 
progression in the brains of rats with chronic ischemia.   
In the present study, we investigated the therapeutic effects 
of citicoline in chronic cerebral hypoperfusion induced in 
rats by conducting a histopathologic investigation and cogni-
tive-behavior test. 
 
Methods 
 
Experimental animals 
All procedures used in this study were approved by the 
Institutional Animal Care and Use Committee (IACUC) at 
the College of Medicine, The Catholic University of Korea. 
Ten-week-old male Wistar rats weighing 280-300 g (Joong-
ang Lab, Seoul, Korea) were used in this study. The rats were 
housed at a temperature of 23-26℃  and a humidity of 50% 
with a 12-h light-dark cycle, and they were allowed free ac-
cess to food and water except when performing the eight-
arm radial maze. 
 
Operation 
All surgical procedures were carried out under inhalation an-
esthesia using 2% isofluorane with 30% O2 and 70% N2, and 
the body temperature was maintained during the operation at 
37.0-37.8℃  using a temperature controller. After fixing a rat 
in the prone position on a board, a skin incision about 2 cm 
long was made and a cervical central line was placed. The bi-
lateral common carotid arteries were exposed by isolating them 
from the vagus nerve and its sheath, and they were double 
ligated with 4-0 silk at 8-10 mm below the visible region of 
the external carotid artery. 
 
Administration 
Animals were divided into immediate- and delayed-treatment 
groups. Those in the immediate-treatment group received a 
sham operation (n=8), citicoline (Somazina, Bukwang, Korea) 
administered intraperitoneally (500 mg/kg/day) for 3 weeks 
immediately after the operation (n=9), or phosphate buffered 
saline (PBS)(n=7). 
Rats in the delayed-treatment group were administered in-
traperitoneally with 500 mg/kg/day citicoline (n=8) or PBS 
(n=8) for 21 days beginning on the 8th day after the operation. 
Rats in the immediate-treatment group were given 500 mg/ 
kg/day citicoline for 3 weeks beginning immediately after 
the operation.
13 PBS was administered at the same dosage in 
control animals. In addition, the chronic effects of citicoline 
on the progression of vascular change were examined in the 
delayed-treatment group. 
 
Spatial memory test 
The spatial memory test was performed in an eight-arm ra-
dial maze comprising a center with a radius of 34 cm and eight 
arms (60 cm long and 12 cm wide) with walls 20 cm high. 
Rats were trained twice daily for 10 days before model pro-
duction, and rats with less than two total errors (TEs) were 
selected for further testing. The rats were then fed ad libitum 
for 3 hours and then fasted. Four of the eight arms in the 
maze contained 40-50 mg of feed that was placed in the same 
place every day. Considering the visual loss after model pro-
duction, the floor paper in each arm had a different texture in 
order to allow the rats to identify the arms containing feed.
14 
The rats were placed in the center of the maze, and a test was 
carried out for 10 minutes to see if the rats ate all of the feed. 
A TE, reference memory error (RME), or walking memory 
error (WME) was considered to have occurred if the rat went 
to the arm without feed, went to the arm without feed for the 
first time, or returned to the arm without feed after eating, 
respectively. The time taken to eat all of the feed was recorded. 
 
Tissue preparation 
Rats were deeply anesthetized with 30% urethane, perfused 
transcardially with 0.01 M PBS, and then perfused with a fix-
ative containing 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4) containing 0.2% glutaraldehyde. The brain 
was extracted and fixed again with the fixative for 4 hours 
and soaked in a 30% sucrose solution until it sank. It was 
then quick-frozen with liquid nitrogen and stored at -70℃. 
Slices with thicknesses of 25 and 6 μm were then made by cut-
ting at 2.8-3.14 mm posterior to the bregma using a cryomi-
crotome in accordance with the atlas of Paxinos and Watson.
15 
 
Klüver-barrera staining 
Each 25-μm-thick section was soaked in 0.1% Solvent Blue 
38 (Sigma, USA) solution at 60℃ overnight, and the dye 
was removed (except for that in the WM region) using lithium 
carbonate solution, distilled water, and 70% ethanol. The sec-
tion was soaked in 0.1% cresyl violet (Sigma) solution for 15 
minutes, and then in 95% ethanol followed by 100% ethanol 
and xylene for dehydration and transparency. After mounting, 
pathological findings in the optic tract, internal capsule, and 
corpus callosum were observed using an optical microscope 
at 200× magnification. The severity of the WM lesion was  
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classified as normal (grade 0), disarrangement of nerve fibers 
(grade 1), formation of marked vacuoles (grade 2), and disa-
ppearance of myelinated fibers (grade 3).
16 
 
The terminal deoxynucleotidyl transferase biotin-
dUTP nick end labelling staining 
The terminal deoxynucleotidyl transferase biotin-dUTP nick-
end-labeling (TUNEL) assay was performed on 6-μm-thick 
brain sections using fluorescein with the In Situ Cell Death 
Detection Kit (Roche, Germany). TUNEL-positive cells were 
then examined using a fluorescent microscope. 
 
Statistical analysis 
The results were analyzed by SigmaPlot 2000 V6.0 and SPSS 
V10.0 statistical package and are presented here as mean±SEM 
values. Statistical analysis was performed by one-way analy-
sis of variance. Differences were designated as significant 
when p<0.05. 
 
Results 
 
Spatial Memory Test 
The eight-arm radial maze test was carried out for 5 days 
before sacrificing the animals. In the immediate-treatment 
group on the first day, the number of TEs did not differ sig-
nificantly between sham (5.56±1.45) and citicoline (5.05±0.64) 
treatments but it did differ between PBS treatment (7.21± 
1.17) and sham and citicoline treatments. The total time spent 
and number of RMEs were somewhat higher for PBS treat-
ment (338.57±35.24 s and 3.21±0.28, respectively) than for 
sham (278.88±56.50 s and 2.5±0.39) and citicoline (294.88± 
34.03 s and 2.66±0.25) treatments. In the last 5 days, there 
were decreases in TEs, time spent, and RMEs for all treat-
ments: 1.25±0.42, 113.06±16.96 s, and 0.75±0.18, respec-
tively, for sham treatment; 2.61±0.68, 131.06±26.76 s, and 
1.27±0.33 for citicoline treatment; and 4.42±1.52, 246.64± 
49.11 s, and 2.00±0.34 for PBS treatment (Fig. 1). No signi-
ficant difference was found in the frequency of WMEs, but 
the frequency was too low to determine the effect of citico-
line on short-term memory disorder. 
In the delayed-treatment group, the number of TEs did not 
differ significantly between citicoline (6.25±1.34) and PBS 
(6.31±0.87) treatments on the first day. However, from the 
second day, the difference in the number of TEs between 
citicoline and PBS treatments gradually increased over time, 
eventually becoming significant (at 3.12±0.65 and 4.00±0.64, 
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Fig. 1. Eight-arm radial maze test of immediate treatments with citicoline, PBS, and a sham operation. Number of TEs (A), number of RMEs 
(B), and time spent (C). †p<0.05 vs citicoline treatment, §p<0.05 vs citicoline treatment, *p<0.05, **p<0.01 vs. sham operation. PBS: pho-
sphate buffered saline, TEs: total error, RMEs: reference memory errors. 
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Fig. 2. Eight-arm radial maze test of delayed treatments with citicoline, PBS, and a sham operation. Number of TEs (A), number of RMEs (B),
time spent (C). *p<0.05, **p<0.01. PBS: phosphate buffered saline, TEs: total error, RMEs: reference memory errors. 
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Fig. 3. Klüver-Barrera staining for WM damage. Corpus callosum and optic tract of rats that received a sham operation, citicoline, or PBS in
the immediate-treatment (A) and delayed-treatment (B) groups. Schematic representation of the rat brain at 3.14 mm posterior to the bre-
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treatment (E) groups. The WM damage was greatest in the optic tract, with less intense changes observed in the medial part of the corpus cal-
losum. Note that citicoline caused less serious WM damage than PBS in both the optic tract and corpus callosum in the immediate-treatment
group, whilst there was no significant difference in the delayed-treatment group. Scale bars in A, B=60 μm. *p<0.01, **p<0.001. WM: white 
matter, PBS: phosphate buffered saline.  
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respectively) on the 5th day. The time spent did not differ 
between citicoline and PBS treatments on the 1st day (423.81± 
58.76 and 426.25±47.93 s, respectively) but it did on the 5th 
day (178.37±37.05 and 223.43±40.80 s). In addition, the fre-
quency of memory errors eventually differed significantly be-
tween citicoline treatment (2.87±0.30 and 1.81±0.33 on the 
1st and 5th days, respectively) and PBS treatment (3.12±0.24 
and 2.68±0.32)(Fig. 2). The frequency of WMEs did not 
differ significantly in the delayed-treatment group. 
 
Pathologic examination 
 
Examination of white matter changes 
Rats in the immediate-treatment group showed marked differ-
ences in the optic tract, some differences in the corpus cal-
losum (Fig. 3A and B), and few changes in the internal capsule 
and other WM regions. The extent of WM changes in the optic 
tract and corpus callosum of rats was graded according to the 
standard of Wakita et al.
13 as follows: 0.23±0.04, 1.52±0.13, 
and 1.85±0.15 for sham, citicoline, and PBS treatments, res-
pectively, in the optic tract; and 0.20±0.04, 0.50±0.08, and 
0.88±0.17 in the corpus callosum (p<0.05). 
In the delayed-treatment group, WM changes were obser-
ved in the optic tract and corpus callosum, but there was no 
significant difference between citicoline and PBS treatments: 
2.09±0.09 and 1.98±0.12, respectively, in the optic tract; and 
0.83±0.09 and 0.96±0.13 in the corpus callosum (Fig. 3D and E). 
 
Observation of TUNEL-positive cells 
There were TUNEL-positive cells around cortex and lateral 
ventricles (Fig. 4C and D) as well as in the WM (Fig. 4A and B), 
but not in the hippocampus. 
The number of TUNEL-positive cells that were also sta-
ined with DAPI (excluding positive cells in vessels of se-
ctions)17 (Fig. 4E) was significantly higher for citicoline 
(12.66±4.29 cells) and PBS (17.42±6.94 cells) treatments 
than for the sham treatment (2.62±0.88 cells) in the imme-
diate-treatment group (Fig. 4F). Similar numbers of TUNEL-
positive cells were observed in the delayed-treatment group, 
but there was no significant difference between citicoline 
and PBS treatments (12.75±1.71 and 14.37±2.42, respecti-
vely)(Fig. 4G). 
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Fig. 4. TUNEL staining in the immediate-treatment group. TUNEL-positive cells were evident both in WM such as the optic tract (A) and 
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TUNEL-positive cells was lower for citicoline treatment than for PBS treatment in the immediate-treatment group, whilst there was no 
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transferase biotin-dUTP nick end labelling, WM: white matter.  
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Discussion 
 
In the immediate-treatment group, WM damage and apopto-
sis were lower for citicoline treatment than for PBS treatment. 
Phosphatidylcholine is a cell membrane component that is 
degraded during cerebral ischemia into free fatty acids and 
free radicals.
18,20 Because citicoline is an intermediate in the 
synthesis of phosphatidylcholine, it might counter the pro-
gression of ischemic damage by reducing the release of free 
fatty acids
18,20 and by recovering activities of mitochondrial 
ATPase and membrane Na
+/K
+ ATPase.
18 Also, it prevents 
apoptosis by improving membrane recovery.
19 These findings 
are consistent with our results. Therefore, citicoline improves 
memory and learning ability by reducing the number of is-
chemic lesions and exerting neuroprotective effects on ische-
mia via the above mechanisms. 
In the delayed-treatment group, WM lesions and apoptosis 
did not differ between citicoline and PBS treatments, but 
there was an improvement in cognitive ability. These results 
indicate that citicoline acts via a different mechanism in addi-
tion to neuroprotection in cognitive improvement. Although 
the exact mechanism of cognitive improvement is not known, 
citicoline might prevent cognitive impairment by increasing 
phospholipids, which have an important role in neurotrans-
mission,
21 and by increasing the levels of norepinephrine and 
dopamine,
22 which are known to be neurotransmitters involv-
ed in cognition. Further study is needed to elucidate the ac-
tual mechanism. 
Citicoline is used as an immediate treatment for neuropro-
tection in patients with acute stroke, but the effects of delayed 
treatment of citicoline on cognition have been unclear. This 
study confirms that delayed treatment improves the cognitive 
decline that is a typical symptom in dementia. Therefore, it is 
likely that citicoline can be applied more widely in patients 
with vascular dementia. 
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